Show simple item record

dc.contributor.advisorEkincioğlu, Aygin
dc.contributor.authorÖztürk, Zeynep
dc.date.accessioned2023-08-15T11:36:13Z
dc.date.issued2023-08-08
dc.date.submitted2023-08-02
dc.identifier.citationÖztürk, Z., Nefroloji Polikliniğinde Takibi Yapılan Hastalarda Sodyum-Glukoz Ko-Transporter 2 (SGLT-2) İnhibitörlerinin Kullanımının Değerlendirilmesi, Hacettepe Üniversitesi, Sağlık Bilimleri Enstitüsü, Klinik Eczacılık Programı Yüksek Lisans Tezi, Ankara, 2023.tr_TR
dc.identifier.urihttps://hdl.handle.net/11655/33917
dc.description.abstractOzturk, Z., Evaluation of the Use of Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors in Patients Followed Up in the Nephrology Outpatient Clinic, Hacettepe University Graduate School of Health Sciences, Master Thesis in Clinical Pharmacy, Ankara, 2023. Approximately 10% of the adult population has at least one type of kidney damage. It has been known that the quality of life is low and the mortality and morbidity rates are 10-30 times higher in patients with kidney disease. The use of sodium glucose co-transporter2 (SGLT-2) inhibitors in diabetic and non-diabetic patients has increased in recent years due to their renoprotective and cardioprotective effects. In this study, it was aimed to evaluate the effects of the use of SGLT-2 inhibitors on kidney disease and prognosis in patients followed in the Hacettepe University Hospitals Nephrology Department outpatient clinic, and to evaluate the nephrotoxicity risk of other drugs used by the patients. The study also aimed to evaluate the quality of life of the patients. The study was conducted prospectively between September 2022 and February 2023 and a total of 72 patients (50% female) were included with a median age (range) of 65 (35-83) years. The patients were monitored for a median duration of 4 months, and decreases in the risk scores of 2 (p=0,165) and 5 years (p=0,227) of kidney failure and cardiovascular disease (p<0.001) were observed. The mean numbers of nephrotoxic drugs and nephrotoxicity score were 1.76 (0.91) and 1.51 (0.85), respectively; where the nephrotoxicity score was observed as 1.69 (0.93) in patients using empagliflozin. The quality of life of patients with kidney disease was determined as good (mean: 88.51) for the symptoms and problems of the disease, but as poor (mean: 42.53) for the patient's physical condition. In conclusion, although the positive effects of the use of SGLT-2 inhibitors on clinical outcomes in patients with kidney disease have been demonstrated, the evaluation of other drugs used in patients by clinical pharmacists particularly in terms of nephrotoxicity, and by the provision of multidisciplinary care services may increase the success rate in the treatment.tr_TR
dc.description.abstractOzturk, Z., Evaluation of the Use of Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors in Patients Followed Up in the Nephrology Outpatient Clinic, Hacettepe University Graduate School of Health Sciences, Master Thesis in Clinical Pharmacy, Ankara, 2023. Approximately 10% of the adult population has at least one type of kidney damage. It has been known that the quality of life is low and the mortality and morbidity rates are 10-30 times higher in patients with kidney disease. The use of sodium glucose co-transporter2 (SGLT-2) inhibitors in diabetic and non-diabetic patients has increased in recent years due to their renoprotective and cardioprotective effects. In this study, it was aimed to evaluate the effects of the use of SGLT-2 inhibitors on kidney disease and prognosis in patients followed in the Hacettepe University Hospitals Nephrology Department outpatient clinic, and to evaluate the nephrotoxicity risk of other drugs used by the patients. The study also aimed to evaluate the quality of life of the patients. The study was conducted prospectively between September 2022 and February 2023 and a total of 72 patients (50% female) were included with a median age (range) of 65 (35-83) years. The patients were monitored for a median duration of 4 months, and decreases in the risk scores of 2 (p=0,165) and 5 years (p=0,227) of kidney failure and cardiovascular disease (p<0.001) were observed. The mean numbers of nephrotoxic drugs and nephrotoxicity score were 1.76 (±0.91) and 1.51 (±0.85), respectively; where the nephrotoxicity score was observed as 1.69 (±0.93) in patients using empagliflozin. The quality of life of patients with kidney disease was determined as good (mean: 88.51) for the symptoms and problems of the disease, but as poor (mean: 42.53) for the patient's physical condition. In conclusion, although the positive effects of the use of SGLT-2 inhibitors on clinical outcomes in patients with kidney disease have been demonstrated, the evaluation of other drugs used in patients by clinical pharmacists particularly in terms of nephrotoxicity, and by the provision of multidisciplinary care services may increase the success rate in the treatment.tr_TR
dc.language.isoturtr_TR
dc.publisherSağlık Bilimleri Enstitüsütr_TR
dc.rightsinfo:eu-repo/semantics/openAccesstr_TR
dc.subjectSGLT-2 inhibitörütr_TR
dc.subjectYaşam kalitesi
dc.subjectNefroloji
dc.subjectKlinik eczacı
dc.subject.lcshEczacılık bilimitr_TR
dc.titleNefroloji Polikliniğinde Takibi Yapılan Hastalarda Sodyum-Glukoz Ko-Transporter 2 (Sglt-2) İnhibitörlerinin Kullanımının Değerlendirilmesitr_TR
dc.typeinfo:eu-repo/semantics/masterThesistr_TR
dc.description.ozetÖztürk, Z., Nefroloji Polikliniğinde Takibi Yapılan Hastalarda Sodyum-Glukoz Ko-Transporter 2 (SGLT-2) İnhibitörlerinin Kullanımının Değerlendirilmesi, Hacettepe Üniversitesi, Sağlık Bilimleri Enstitüsü, Klinik Eczacılık Programı Yüksek Lisans Tezi, Ankara, 2023. Erişkin nüfusun yaklaşık %10’unda en az bir çeşit böbrek hasarı olduğu ve böbrek hastalığı olanlarda yaşam kalitesinin düşük, mortalite ve morbiditenin 10-30 kat daha yüksek olduğu bilinmektedir. Sodyum glukoz ko-transporter 2 (SGLT-2) inhibitörlerinin, renoprotektif ve kardiyoprotektif etkileri sebebiyle son yıllarda diyabetik ve non-diyabetik hastalarda kullanımı artmıştır. Bu çalışmada, Hacettepe Üniversitesi Hastaneleri Nefroloji Bilim Dalı polikliniğinde takibi yapılan hastalarda SGLT-2 inhibitörlerinin kullanımının böbrek hastalığı ve prognozuna olan etkisinin ve hastaların kullandığı diğer ilaçların nefrotoksisite riski açısından değerlendirilmesi amaçlanmıştır. Ayrıca hastaların yaşam kalitesinin değerlendirilmesi hedeflenmiştir. Çalışma Eylül 2022-Şubat 2023 tarihleri arasında prospektif olarak yürütülmüş ve toplam 72 hasta dahil edilmiştir. Hastaların 36 (%50)’sı kadın ve genel yaş ortancası (minimum-maksimum) 65 (35-83) yıldır. Hastalar ortanca 4 ay süre ile takip edilmiş olup, 2 yıllık (p=0,227) ve 5 yıllık (p=0,165) böbrek hastalığı ve kardiyovasküler hastalık risk puanlarında (p<0,001) azalma saptanmıştır. Hastaların kullandığı nefrotoksik ilaç sayısı ve nefrotoksisite puanı ortalama (±standart sapma) 1,76 (±0,91) ve 1,51 (±0,85) olarak saptanmış ve empagliflozin kullanan hastalarda nefrotoksisite skoru 1,69 (±0,93) olarak gözlenmiştir. Böbrek hastalığı olan hastaların yaşam kalitesi; hastalığın semptom ve problemleri açısından iyi (ortalama: 88,51); hastanın fiziksel durumuna olan etki açısından daha kötü (ortalama: 42,53) olduğu saptanmıştır. Sonuç olarak, böbrek hastalarında SGLT-2 inhibitörlerinin kullanımının klinik sonuçlara olumlu etkileri gösterilmiş olmakla birlikte, hastalarda kullanılan diğer ilaçların da, özellikle nefrotoksisite açısından, klinik eczacılar tarafından değerlendirilmesi ve multidisipliner bakım hizmetlerinin sunulması ile tedavi sürecinde başarı oranını artırabilecektir.tr_TR
dc.contributor.departmentKlinik Eczacılıktr_TR
dc.embargo.termsAcik erisimtr_TR
dc.embargo.lift2023-08-15T11:36:13Z
dc.fundingYoktr_TR


Files in this item

This item appears in the following Collection(s)

Show simple item record